AZNAstraZeneca PLC

AZN Stock Price, Valuation & Chart | AstraZeneca PLC

Compare

$162.47+0.34 (+0.21%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - General AZN intrinsic value AZN calculated fair value vs price

Overview Financials Dividends Ratios

AZN Historical price chart

AZN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization251.97B

PE Ratio17.55

EPS9.26

Trading Volume2.60M

Today's High/Low164.24/161.38

Dividend Yield1.31

52 Week High/Low212.71/145.8

Shares Outstanding1.55B

AZN Financial Statement

AZN Analyst ratings

AZN Analysis & performance metrics

AZN Company profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed…

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort,…

AZN Management team

Name

Position

Pascal Claude Roland Soriot D.V.M., M.B.A.CEO

Chief Executive Officer & Executive Director

Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology Haematology R&D

Ruud Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Gonzalo Vina

Head of Global Media Relations

Jeffrey Pott J.D.

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

Aradhana Sarin M.D.CFO

Chief Financial Officer & Executive Director

Pam P. Cheng

EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Name

Position

Pascal Claude Roland Soriot D.V.M., M.B.A.CEO

Chief Executive Officer & Executive Director

Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology Haematology R&D

Ruud Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Gonzalo Vina

Head of Global Media Relations

Jeffrey Pott J.D.

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

Aradhana Sarin M.D.CFO

Chief Financial Officer & Executive Director

Pam P. Cheng

EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Management Team

Pascal Claude Roland Soriot D.V.M., M.B.A.CEO

Chief Executive Officer & Executive Director

Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology Haematology R&D

Ruud Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Gonzalo Vina

Head of Global Media Relations

Jeffrey Pott J.D.

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

Aradhana Sarin M.D.CFO

Chief Financial Officer & Executive Director

Pam P. Cheng

EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Management

Pascal Claude Roland Soriot D.V.M., M.B.A.CEO

Chief Executive Officer & Executive Director

Susan Mary Galbraith M.D., Ph.D.

Executive Vice President of Oncology Haematology R&D

Ruud Dobber Ph.D.

Executive Vice-President of BioPharmaceuticals Business Unit

Gonzalo Vina

Head of Global Media Relations

Jeffrey Pott J.D.

CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board

David Fredrickson

Executive Vice-President of Oncology Haematology Business Unit

Aradhana Sarin M.D.CFO

Chief Financial Officer & Executive Director

Pam P. Cheng

EVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board

Total 8 executives

AZN Frequently asked questions

What is AstraZeneca PLC (AZN) Stock Price?

Current stock price of AstraZeneca PLC (AZN) stock is $162.47. The stock price is +0.21% higher in the session. The intraday range can be seen from this page. Volume of AstraZeneca PLC (AZN) stock is 2.60M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the AstraZeneca PLC (AZN) stock price going up or down today?

The stock price of AstraZeneca PLC (AZN) can change with earnings, company news, and overall market sentiment. AstraZeneca PLC operates in the Healthcare / Drug Manufacturers - General market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the AstraZeneca PLC stock expensive at its current price?

Whether AstraZeneca PLC looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AZN on this page is 17.55. EPS on this page is 9.26. Compare those figures with peers and growth expectations before deciding if the current AstraZeneca PLC price is justified.

How has the stock price of AstraZeneca PLC (AZN) performed historically?

Historical performance for AstraZeneca PLC (AZN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AZN reacted to past earnings and market events.

Should I buy AstraZeneca PLC (AZN) stock, at this price?

Buying AstraZeneca PLC (AZN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.